as 09-05-2025 4:00pm EST
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
Founded: | 2007 | Country: | United States |
Employees: | N/A | City: | BOSTON |
Market Cap: | 396.8M | IPO Year: | 2021 |
Target Price: | $22.29 | AVG Volume (30 days): | 139.6K |
Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -1.95 | EPS Growth: | N/A |
52 Week Low/High: | $4.34 - $12.38 | Next Earning Date: | 08-13-2025 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
Elazzouzi Amy | AURA | Senior Vice President, Finance | Aug 18 '25 | Sell | $6.70 | 7,722 | $51,737.40 | 86,558 |
AURA Breaking Stock News: Dive into AURA Ticker-Specific Updates for Smart Investing
MT Newswires
4 months ago
GlobeNewswire
4 months ago
MT Newswires
4 months ago
GlobeNewswire
4 months ago
GlobeNewswire
4 months ago
GlobeNewswire
4 months ago
Insider Monkey
5 months ago
GlobeNewswire
5 months ago
The information presented on this page, "AURA Aura Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.